AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Enanta Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

December 30, 2019 GMT

WATERTOWN, Mass.--(BUSINESS WIRE)--Dec 30, 2019--

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will make a formal presentation at the 38 th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. Pacific Time. The presentation will contain a business overview and an update on Enanta’s research and development programs. A separate question and answer session with investors will follow the presentation and will be webcast.

Webcast Information
Enanta’s presentation will take place on January 13, 2020 beginning at 2:30 p.m. Pacific Time. A live webcast of the presentation, as well as the question and answer session that follows the presentation, will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcasts will be and will be archived for approximately 30 days.

About Enanta
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis B virus (HBV).

Enanta’s research and development activities are funded by royalties from HCV products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by AbbVie in numerous countries as part of its leading treatment for chronic hepatitis C virus (HCV) infection sold under the tradenames MAVYRET ® (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191230005014/en/

CONTACT: Investor Contact

Carol Miceli

617-607-0710

cmiceli@enanta.comMedia Contact

Kari Watson

MacDougall Biomedical Communications

781-235-3060

kwatson@macbiocom.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH SCIENCE PHARMACEUTICAL RESEARCH

SOURCE: Enanta Pharmaceuticals, Inc.

Copyright Business Wire 2019.

PUB: 12/30/2019 07:30 AM/DISC: 12/30/2019 07:30 AM

http://www.businesswire.com/news/home/20191230005014/en